647
Views
13
CrossRef citations to date
0
Altmetric
Review

Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer

, , , &
Pages 1209-1223 | Received 16 May 2016, Accepted 14 Jul 2016, Published online: 05 Aug 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jing Xue, Jiali Yang, Meihui Luo, William C. Cho & Xiaoming Liu. (2017) MicroRNA-targeted therapeutics for lung cancer treatment. Expert Opinion on Drug Discovery 12:2, pages 141-157.
Read now

Articles from other publishers (12)

Thi-Oanh Tran, Luu Ho Thanh Lam & Nguyen Quoc Khanh Le. (2023) Hyper-methylation of ABCG1 as an epigenetics biomarker in non-small cell lung cancer. Functional & Integrative Genomics 23:3.
Crossref
Min Huang, Fang He, Dan Li, Ya-Jia Xie, Ze-Bo Jiang, Ju-Min Huang, Xiao-Ping Zhao, Ali Adnan Nasim, Jun-Hui Chen, Jin-Cai Hou, Xian-Ming Fan, Elaine Lai-Han Leung & Xing-Xing Fan. (2022) PA-MSHA induces inflamed tumor microenvironment and sensitizes tumor to anti-PD-1 therapy. Cell Death & Disease 13:11.
Crossref
Xuezhong Shi, Ani Dong, Xiaocan Jia, Guowei Zheng, Nana Wang, Yuping Wang, Chaojun Yang, Jie Lu & Yongli Yang. (2022) Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma. Frontiers in Immunology 13.
Crossref
Xiao Huo, Xi Zhang, Shuhong Li, Shuzhen Wang, Hengzi Sun & Mo Yang. (2022) Identification of Novel Immunologic Checkpoint Gene Prognostic Markers for Ovarian Cancer. Journal of Oncology 2022, pages 1-18.
Crossref
Junyan Liang, Yue Wang, Ling Zheng & Hui Mei. (2022) A Clinical Study on the Use of Yiqi Yangxue Decoction Combined with Chemotherapy to Promote Rapid Postoperative Recovery in Patients with Non-Small Cell Lung Cancer. Emergency Medicine International 2022, pages 1-6.
Crossref
Przemyslaw Wielgat, Katarzyna Niemirowicz-Laskowska, Agnieszka Z. Wilczewska & Halina Car. (2021) Sialic Acid—Modified Nanoparticles—New Approaches in the Glioma Management—Perspective Review. International Journal of Molecular Sciences 22:14, pages 7494.
Crossref
Seyed Mohammad Miri, Elham Tafsiri, William Chi Shing Cho & Amir Ghaemi. (2020) CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy. Cancer Cell International 20:1.
Crossref
Feng Jiang, Chuyan Wu, Ming Wang, Ke Wei, Guoping Zhou & Jimei Wang. (2020) Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma. Clinica Chimica Acta 511, pages 306-318.
Crossref
Hongshu Sui, Ningxia Ma, Ying Wang, Hui Li, Xiaoming Liu, Yanping Su & Jiali Yang. (2018) Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research 2018, pages 1-17.
Crossref
Hui Li, Ningxia Ma, Jing Wang, Ying Wang, Chao Yuan, Jing Wu, Meihui Luo, Jiali Yang, Juan Chen, Juan Shi & Xiaoming Liu. (2018) Nicotine Induces Progressive Properties of Lung Adenocarcinoma A549 Cells by Inhibiting Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Expression and Plasma Membrane Localization. Technology in Cancer Research & Treatment 17, pages 153303381880998.
Crossref
Xiaoming Liu & William C. Cho. (2017) Precision medicine in immune checkpoint blockade therapy for non‐small cell lung cancer. Clinical and Translational Medicine 6:1.
Crossref
Min Huang, Fang He, Dan Li, Ya-Jia Xie, Zebo Jiang, Jumin Huang, Xiao-Ping Zhao, Ali Adnan Nasim, Jun-Hui Chen, Jincai Hou, Xian-Ming Fan, Elaine Lai-Han Leung & Xing Xing Fan. (2022) PA-MSHA Induces Inflamed Tumor Microenvironment and Sensitizes Tumor to Anti-PD-1 Therapy. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.